Metabolic diseases—including type 2 diabetes, dyslipidemia, non-alcoholic fatty liver disease (NAFLD), and obesity—are increasing globally and share a central pathogenic mechanism: the accumulation of excess fat in non-adipose tissues, resulting in insulin resistance and organ dysfunction [1,2,3]. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.